Evidence map›Paper›PMID 40965328›Full record

ArticleActa oncologica (Stockholm, Sweden)2025

Impact of radiation dose on neurocognitive function and quality of life in long-term survivors of childhood brain tumour.

Laura Toussaint, Anne Sophie Lind Helligsø, Ludvig Paul Muren, Ali Amidi, Rikke Hedegaard Dahlrot, Louise Tram Henriksen, Maja Vestmø Maraldo, Martin Skovmos Nielsen, Anouk Kirsten Trip, Lisa Maria Wu and 1 more

Abstract read
In one paragraph

Article in Acta oncologica (Stockholm, Sweden), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Laura ToussaintDanish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. lautou@rm.dk.
Anne Sophie Lind HelligsøDepartment of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Pediatrics and Adolescent Medicine, Gødstrup Hospital, Gødstrup, Denmark.ORCID 0000-0003-4956-4897
Ludvig Paul MurenDanish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.ORCID 0000-0002-7418-5832
Ali AmidiUnit for Psycho Oncology & Health Psychology, Department of Psychology and Behavioral Sciences, Aarhus University, Aarhus, Denmark.ORCID 0000-0003-2921-9797
Rikke Hedegaard DahlrotDepartment of Oncology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Denmark.ORCID 0000-0003-1538-4361
Louise Tram HenriksenDepartment of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0002-9350-1538
Maja Vestmø MaraldoDepartment of Oncology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-6159-5907
Martin Skovmos NielsenDepartment of Oncology, Aalborg University Hospital and Clinical Cancer Research Center, Aalborg, Denmark.ORCID 0000-0002-3955-7266
Anouk Kirsten TripDanish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0001-9600-6236
Lisa Maria WuUnit for Psycho Oncology & Health Psychology, Department of Psychology and Behavioral Sciences, Aarhus University, Aarhus, Denmark; Department of Psychology, Reykjavik University, Reykjavik, Iceland.ORCID 0000-0003-2241-9905
Yasmin Lassen-RamshadDanish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0002-4992-3231

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeChildren treated with radiotherapy (RT) for a brain tumour often exhibit neurocognitive impairment and report lower quality of life (QoL) later in life. The aim of this nationwide cross-sectional cohort study was to explore the impact of RT dose to brain organs at risk (OARs) on neurocognition and QoL in long-term survivors of childhood brain tumours. Patient/material and methods: A total of 132 survivors of childhood brain tumours, diagnosed from 2001 to 2017 in Denmark, underwent neurocognitive tests and QoL questionnaires at least 5-years post-diagnosis. Neurocognitive assessments were complete and available for 86 patients (61 no-RT/25 RT), and QoL scores for 107 (79 no-RT/28 RT). Mann Whitney U-tests were used to compare scores between no-RT and RT groups. For scores impacted by RT, OAR-specific robust linear regressions were performed to evaluate RT dose effects while adjusting for potential confounders.

resultsClinically significant overall cognitive impairment was observed for 55% of the neurocognitive sub-cohort, with younger age at treatment time as a significant risk factor, while hydrocephalus status had no impact. There were no statistically significant differences on neurocognitive tests between the RT and no-RT group. However, patients treated with RT had significantly lower scores on the physical and social functioning QoL domains, with mean dose to the pituitary gland and left hippocampus, respectively, as significant predictors.

interpretationThis cross-sectional study indicates that RT dose-effects, particularly in the pituitary gland and left hippocampus, might contribute to reduced QoL in survivors of childhood brain tumours.

Indexed as

Brain NeoplasmsCancer SurvivorsCognitionQuality of LifeAdolescentAdultChildChild, PreschoolCross-Sectional StudiesDenmarkFemaleHumansInfantMaleNeuropsychological TestsOrgans at Risk

Identifiers

PMID40965328
PMCPMC12452035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.